Medpace (NASDAQ:MEDP) Upgraded at UBS Group

UBS Group upgraded shares of Medpace (NASDAQ:MEDP) to a hold rating in a report issued on Wednesday morning,Zacks reports.

A number of other analysts have also recently commented on MEDP. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Finally, Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $602.27.

Medpace Stock Performance

Shares of MEDP opened at $599.47 on Wednesday. The business has a 50-day moving average of $599.95 and a 200 day moving average of $521.18. Medpace has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a market cap of $16.73 billion, a P/E ratio of 35.14, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace will post 17.54 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, CEO August Troendle sold 49,018 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the transaction, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have sold 336,140 shares of company stock worth $208,008,328. 20.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Medpace

Several large investors have recently added to or reduced their stakes in the business. Cim Investment Management Inc. raised its holdings in shares of Medpace by 7.3% in the 2nd quarter. Cim Investment Management Inc. now owns 1,137 shares of the company’s stock valued at $602,000 after acquiring an additional 77 shares in the last quarter. State Street Corp grew its holdings in shares of Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after purchasing an additional 28,666 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Medpace by 38.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock worth $10,615,000 after purchasing an additional 5,610 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Medpace by 8.2% in the second quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company’s stock worth $587,000 after purchasing an additional 84 shares during the last quarter. Finally, Tidal Investments LLC increased its position in shares of Medpace by 8.0% in the second quarter. Tidal Investments LLC now owns 6,155 shares of the company’s stock worth $3,260,000 after purchasing an additional 458 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “hold” and raised its price target to $673 from $405. The new target is above recent trading levels, suggesting UBS sees reduced downside risk. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest quarterly results remain supportive of its growth story: revenue rose 17.2% year over year to $707.3 million, while earnings of $4.25 per share exceeded the $3.98 consensus estimate. Fiscal 2026 earnings guidance also remains intact.
• Neutral Sentiment: Analyst sentiment is broadly mixed, with most firms maintaining “hold” ratings. The consensus price target is approximately $602.27, close to recent levels, indicating that much of the company’s growth may already be reflected in its valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, after selling 26,701 shares worth about $16.6 million on September 29. The combined sales totaled roughly $30.3 million and materially reduced his direct ownership. Additional smaller sales were also reported, raising concerns about insider confidence and contributing to the stock’s weakness. Troendle nevertheless retains a substantial stake. Medpace CEO stock sale SEC filing

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.